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http://www.molecularpain.com/content/9/1/29RESEARCH Open AccessAn LPA species (18:1 LPA) plays key roles in the
self-amplification of spinal LPA production in the
peripheral neuropathic pain model
Lin Ma1†, Jun Nagai1†, Jerold Chun2 and Hiroshi Ueda1*Abstract
Background: We previously reported that nerve injury-induced neuropathic pain is initiated by newly produced
lysophosphatidic acid (LPA).
Results: In this study, we developed a quantitative mass spectrometry for detecting LPA species by using Phos-tag.
Following nerve injury, the levels of 18:1, 16:0 and 18:0 LPA in the spinal dorsal horn significantly increased at 3 h
and declined at 6 h. Among them, 18:1 LPA level was the most abundant. In the same preparation, there were
significant elevations in the activities of cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase
A2 (iPLA2), key enzymes for LPA synthesis, at 1 h, while there was no significant change in phospholipase A1
activity. Pharmacological studies revealed that NMDA and neurokinin 1 receptors, cPLA2, iPLA2 and microglial
activation, as well as LPA1 and LPA3 receptors were all involved in the nerve injury-induced LPA production, and
underlying cPLA2 and iPLA2 activations. In the cells expressing LPA1 or LPA3 receptor, the receptor-mediated
calcium mobilization was most potent with 18:1 LPA, compared with 16:0 or 18:0 LPA. Moreover, the intrathecal
injection of 18:1 LPA, but not 16:0 or 18:0 LPA, caused a spinal LPA production and neuropathic pain-like behavior.
Conclusion: These results suggest that 18:1 LPA is the predominant ligand responsible for LPA1 and LPA3
receptors-mediated amplification of LPA production through microglial activation.
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Lysophosphatidic acid (LPA) is a lysophospholipid with
a structure comprising a glycerol backbone, a free phos-
phate group, and a single fatty acyl chain. Usually, LPA
consists of several molecular species with different acyl
chains varing in the sn-1 or sn-2 position, the length and
degree of saturation [1,2]. LPA is an important biological
signaling molecule, which is generated in several bio-
logical fluids such as serum, saliva and follicular fluid
[3-5], and in most tissues such as brain, spinal cord and
lung [6,7]. Its landmark roles in various physiological
and pathophysiological conditions, including wound
healing, lung fibrosis, cancer, reproduction, and hair* Correspondence: ueda@nagasaki-u.ac.jp
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reproduction in any medium, provided the orgrowth, have been well-documented [8-12]. These bio-
logical functions have been identified to link with spe-
cific G-protein coupled receptors named LPA1-6 [13,14].
In recent decade, LPA has gained special attention
because of its emerging role as an important risk factor
in chronic neuropathic pain [15-18]. In these studies, we
found the roles of LPA1 signaling for the initiation of
neuropathic pain and its underlying mechanisms, such
as demyelination [19-24]. Among these reports, it should
be noted that the single intrathecal (i.t.) injection of LPA
mimicked the behavioral changes, demyelination and
several biochemical changes caused by nerve injury
[20,23,25]. This unique approach to study neuropathic
pain and its mechanisms was further confirmed by other
groups [26-28]. Emerging findings were observed with
the studies of biosynthesis of LPA in the spinal cord or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duction, measured by biological assay, reached a max-
imum at 3 h after the injury [6], being consistent with
the pharmacological study that the blockade of neuro-
pathic pain was critically observed when LPA1 receptor
antagonist was treated within 2 – 4 h, but not at 6 h
[21]. Similar LPA production was also found with i.t.
LPA treatment [29], suggesting that LPA itself plays im-
portant roles in the amplification of LPA biosynthesis.
Interestingly, LPA-induced amplification of LPA produc-
tion was abolished in Lpar3-deficient (Lpar3-/-) mice
[29], indicating the involvement of LPA3 receptor. More-
over, it should be noted that microglial activation was
also involved in this LPA production [30].
On the other hand, we successfully identified the
species of lysophosphatidylcholine (LPC), the precursor
of LPA, in the spinal dorsal horn after the nerve injury
[31]. In this experiment, the LPC species were simultan-
eously determined by use of nanostructure-assisted laser
desorption/ionization time-of-flight mass spectrometry
system, which removed the need to add chemical matri-
ces for the analysis of small molecules, and enabled to
minimize their background noises [32]. However, it was
difficult to quantitate or even detect any species of LPA
by this system, because of poor ionization due to its
acidic nature and multiple signals derived from free and
salt forms. Recently, this problem was solved by derivati-
zation of LPA molecules using a phosphate-capture mol-
ecule, Phos-tag [33], followed by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry
(MALDI-TOFMS) system [7].
In the present study, we attempted to measure the
LPA production in the spinal dorsal horn following sci-
atic nerve injury by use of this LPA derivatization meth-
odology, and identified the key species of LPA in charge
of amplification of LPA production.Results
Determination of LPA by MALDI-TOFMS using Phos-tag
To detect LPA species, in this study, we developed a quan-
titative MALDI-TOFMS method by use of a phosphate-
capture molecule, Phos-tag, according to previous reports
[7,33,34]. Figure 1a and b present the MALDI-TOF mass
spectrum of internal standard 17:0 LPA, as well as mixture
of authentic standard reagents 16:0, 18:0 and 18:1 LPA
with the internal standard at the level of 0.2 nmol, respect-
ively. Distinctive peaks were detected at m/z 1011, 997,
1023 and 1025, which correspond to 17:0 LPA-Phos-tag,
16:0 LPA-Phos-tag, 18:1 LPA-Phos-tag and 18:0 LPA-
Phos-tag, respectively (Figure 1a and b).
In order to quantify the levels of these LPA species, we
applied each standard LPA (16:0, 18:0 and 18:1 LPA) at 0,
0.1, 0.2, 0.5, 1.0 and 2.0 nmol with 17:0 LPA at 0.2 nmolinto MALDI-TOFMS system. According to the ratios of
ion-peak intensities with each standard LPA to that with
17:0 LPA, the concentration-related linear equations were
established after subtracting the basal background. They
were defined as y = 0.9928x (R2 = 0.9975; x: concentration
ratio of 16:0 to 17:0 LPA, y: intensity ratio of 16:0 to 17:0
LPA), y = 1.4122x (R2 = 0.9923; x: concentration ratio of
18:0 to 17:0 LPA, y: intensity ratio of 18:0 to 17:0 LPA)
and y = 0.3956x (R2 = 0.9971; x: concentration ratio of 18:1
to 17:0 LPA, y: intensity ratio of 18:1 to 17:0 LPA),
responding to 16:0, 18:0 and 18:1 LPA, respectively. In
subsequent studies, LPA equivalents in the extracts from
solid tissue were estimated using these equations based on
linear LPA concentration-dependent responses.
Time-related elevation of nerve injury-induced LPA
production
We analyzed LPA levels in the spinal dorsal horn after
nerve injury by the MALDI-TOFMS system. As shown
in the representative mass spectra of contralateral (con-
trol side) and ipsilateral (injured side) spinal dorsal horn
at 3 h after nerve injury (Figure 1c and d), marked in-
creases of the ion-signal were observed at m/z 997, 1023
and 1025 in the ipsilateral spinal cord, corresponding to
16:0, 18:1 and 18:0 LPA, respectively.
LPA equivalents were calculated based on the linear
equations of each LPA. As shown in Figure 1e, after
nerve injury, the 18:1 LPA level peaked at 3 h, followed
by the slight decline at 6 h. Quite similar changes were
also observed in the 16:0 and 18:0 LPA production
(Figure 1e).
Blockade of nerve injury-induced LPA production
Nerve injury causes the release of pain transmitters such
as glutamate (Glu) and substance P (SP) from primary
afferent fibers, and they activate NMDA and neurokinin
1 (NK1) receptors at the dorsal horn, respectively [18].
Although their roles in neuropathic pain are well known,
the extent of their contribution to LPA production
remains unclear. Here, we injected MK-801 or CP-99994
(10 nmol, i.t.), the antagonists of NMDA or NK1 recep-
tor, respectively [35], at 30 min prior to nerve injury,
and found that both of them significantly blocked nerve
injury-induced LPA production with three species at 3 h
(Figure 2a).
Since cytosolic phospholipase A2 (cPLA2) and calcium-
independent phospholipase A2 (iPLA2) catalyze phos-
phatidylcholine (PC) conversion to LPC [35-37], in this
study, we pre-treated arachidonyl trifluoromethyl ketone
(AACOCF3; 10 nmol, i.t.), a mixed inhibitor of cPLA2 and
iPLA2 [38,39], or bromoenol lactone (BEL; 10 nmol, i.t.), a
specific iPLA2 inhibitor [38], at 30 min before nerve injury.
As shown in Figure 2a, both inhibitors abolished the nerve
injury-induced LPA production (Figure 2a).
Figure 1 Biosynthesis of LPA following nerve injury by MALDI-TOFMS using Phos-tag. (a and b) Representative charts of mass spectra with
internal standard 17:0 LPA (panel a), and mixed standard reagents 16:0, 18:0 and 18:1 LPA as well as internal control (panel b) at the level of
0.2 nmol, following the use of Phos-tag. (c and d) Mass spectra of LPA extracts from the contralateral (panel c) and ipsilateral (panel d) dorsal half
of spinal cord at 3 h after nerve injury. “UI” represents the unidentified compound. (e) Levels of produced LPA species (18:1, 16:0, 18:0 LPA) in
spinal cord preparations of control or injured mice. The capital letter “C” represents the control group (naive mice). Data represent means ± SEM
from experiments using 3-8 mice. *p < 0.05, versus with the control group.
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a microglial activation antagonist [30], completely blocked
injury-induced LPA production (Figure 2a), when it was
pre-treated twice at 1 day and 30 min before injury. In
addition, reverse transcription polymerase chain reaction
(RT-PCR) experiments showed that both LPA1 and LPA3
receptors are expressed in cultured mouse microglia andmouse spinal dorsal horn (Figure 2b). Nociceptive tests
demonstrated that Lpar3-/- mice completely abolished the
nerve injury-induced thermal hyperalgesia (Figure 2c).
Considering the fact that Lpar1-deficient (Lpar1-/-)
mice also showed no neuropathic pain behavior and
underlying mechanisms [20,29], we attempted to see
whether the injury-induced LPA production was affected
Figure 2 Blockade of nerve injury-induced LPA production. (a) Following pre-treatments of vehicle, MK-801, CP-99994, AACOCF3, BEL (each
10 nmol, i.t.) and minocycline (30 mg/ml, i.p.) before nerve injury, the ipsilateral spinal dorsal horn of each mouse was isolated at 3 h after injury.
Levels of LPA species (18:1, 16:0, 18:0 LPA) were measured using such spinal cord preparations by MALDI-TOFMS. Besides, Lpar1- and Lpar3-
deficient mice were also used to evaluate the LPA production at 3 h after injury. The capital letter “C” represents the control group (naive mice).
The “veh”, “MK”, “CP”, “AA” and “mino” represent vehicle, MK-801, CP-99994, AACOCF3 and minocycline, respectively. (b) RT-PCR experiment was
carried out to evaluate the expressions of LPA1 and LPA3 receptors in cultured mouse microglia and mouse spinal dorsal horn. (c) Thermal paw
withdrawal test was performed at time-course points after nerve injury using wild-type or Lpar3-deficient mice. Results represent the threshold of
latency (s) to thermal stimulus. “WT” represents the wide-type mice. Data represent means ± SEM from experiments using 3-8 mice. *p < 0.05,
versus with the control group; #p < 0.05, versus with the vehicle-injury or injury-WT group.
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in Figure 2a, the LPA levels at 3 h after injury were also
abolished in mice deficient of either gene, compared
with wild-type mice.
Blockades of elevated nerve injury-induced cPLA2 and
iPLA2 activities
In this study, the nerve injury-induced activations of
cPLA2 and iPLA2 in the spinal dorsal horn were evalu-
ated by cPLA2 and iPLA2 activity assays. The enzyme
activity of cPLA2 was maximal at 1 h, and slowly
declined to the control level at 3 h (Figure 3a). Although
the maximal activity of iPLA2 was also observed at 1 h,the decline was rapid (Figure 3b). The enhanced cPLA2
activity was abolished by MK-801, CP-99994, AACOCF3
or BEL (each 10 nmol, i.t.), all of which had been
pretreated 30 min before the nerve injury. The pretreat-
ments of minocycline (30 mg/kg, i.p.) 1 day and 30 min
before the injury also abolished the enhanced cPLA2
activity (Figure 3c). All these inhibitors also significantly
inhibited the enhanced iPLA2 activity, though their
sensitivities against iPLA2 were varied among inhibitors
and different from those against cPLA2 (Figure 3d). Among
them, it was noted that MK-801-induced inhibition
of iPLA2 was partial, while BEL inhibited the activity
to the level lower than the uninjured control. Similar
Figure 3 (See legend on next page.)
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Figure 3 Blockade of nerve injury-induced cPLA2 and iPLA2 activations. (a and b) Activation of spinal cPLA2 (panel a) and iPLA2 (panel b)
were detected by cPLA2 and iPLA2 activity assays at defined time points after nerve injury. The capital letter “C” represents the control group
(naive mice). (c and d) After pre-treatments of vehicle, MK-801, CP-99994, AACOCF3, BEL (each 10 nmol, i.t.) and minocycline (30 mg/ml, i.p.)
before nerve injury, the activities of spinal cPLA2 (panel c) and iPLA2 (panel d) at 1 h after injury were evaluated. The “veh”, “MK”, “CP”, “AA” and
“mino” represent vehicle, MK-801, CP-99994, AACOCF3 and minocycline, respectively. (e and f) Activities of cPLA2 (panel e) and iPLA2 (panel f )
were measured at 1 h after injury using the Lpar1- and Lpar3-deficient mice. “WT” represents the wide-type mice. (g) PLA1 activity in the spinal
dorsal horn was measured by PLA1 activity assay at time-course points after nerve injury. Data represent means ± SEM from experiments using
3-6 mice. *p < 0.05, versus with the control group; #p < 0.05, versus with the vehicle/WT-injury group.
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mice (Figure 3e and f ). However, as shown in Figure 3g,
there was no significant change in phospholipase A1
(PLA1) activity after nerve injury.
Cell-type identification of activated cPLA2 in spinal cord
In order to identify the cell-type expressing activated
(phosphorylated) cPLA2 (p-cPLA2) in the spinal cord,
we performed double immunostaining of p-cPLA2 with
antibodies against two kinds of cell-specific markers:
neuronal nuclei (NeuN; neuron) and ionized calcium-
binding adaptor molecule 1 (Iba1; microglia). At 1 h after
nerve injury, most of p-cPLA2 signals co-localized with
NeuN-positive neurons (Figure 4a-c), whose distributionsFigure 4 Cell-type identification of activated cPLA2 in spinal
cord. (a-f) Immunohistochemical double labeling of p-cPLA2 (green)
and NeuN (red) as well as p-cPLA2 (green) and Iba1 (red) in the
spinal cord at 1 h after nerve injury. White arrows represent NeuN-
or Iba1-co-localized p-cPLA2 signals. (g) Low magnification of double
immunostaining with p-cPLA2 (green) and NeuN (red) in the spinal
cord at 1 h after injury. (h) Diagram of Figure 4g. Red dots represent
NeuN co-localized p-cPLA2 signals. Scale bar (including high and low
magnifications), 50 μm.were diffused expressed throughout laminae I-IV layers of
the spinal dorsal horn (Figure 4g and h). On the other
hand, a few signals were also observed in Iba1-positive
microglia (Figure 4d-f). However, there was no p-cPLA2
signal in glial fibrillary acidic protein (astrocyte marker)-
positive cells (data were not shown).
Pharmacological blockade of nerve injury-induced cPLA2
phosphorylation
Double immunostaining with antibodies against p-cPLA2
and NeuN was performed in the spinal cord of control
and pharmacological antagonists-pretreated injured mice.
In control group (naive mice), p-cPLA2 showed a low
expression in neurons. However, nerve injury induced a
significant increase in neuronal p-cPLA2 signals at 1 h
after injury, and the increase was blocked by various
inhibitors, such as MK-801, CP-99994, AACOCF3, BEL
and minocycline, as well as in Lpar1-/- and Lpar3-/-
mice (Figure 5). These findings were in good accord-
ance with those observed in experiments of LPA detec-
tion and cPLA2 and iPLA2 activity assays.
Comparison of LPA1 or LPA3 agonist activities by
different species of LPA
In order to evaluate the agonist potency of each LPA
species, calcium mobilization assay was performed using
B103 cells expressing LPA1 or LPA3 receptor (LPA1-
B103 or LPA3- B103 cells), because both LPA1 and LPA3
receptors enable to induce calcium release from intracel-
lular stores by activating Gq/11-PLCβ-IP3 pathway. As
seen in Figure 6a, when 18:1 LPA at 1-10 μM was added
into the LPA1-B103 cells, a transient increase of cyto-
solic calcium was immediately observed, with a max-
imum at around 30 s after addition, followed by a
gradual decline. Obvious concentration-dependent cal-
cium mobilizations were observed in the range of 3 to
300 nM of 18:1 LPA. The half-maximal effective dose
(ED50) for 18:1 LPA-induced calcium mobilization in
LPA1-B103 cells was calculated as 39.2 nM (Figure 6a).
As shown in Figure 6a-e, similar ED50 (20.8 nM) was
also observed with 20:4 LPA, but little higher values
were with 16:0 and 14:0 LPA (146.3 and 167.8 nM,
respectively). When the maximal effect of 18:1 LPA was
evaluated as 100%, these values of 20:4, 16:0 and 14:0
Figure 5 Blockade of p-cPLA2 signals in spinal neurons after
nerve injury. (a-i) Vehicle, MK-801, CP-99994, AACOCF3, BEL (each
10 nmol, i.t.) and minocycline (30 mg/ml, i.p.) were pre-treated
before nerve injury, and the spinal cord were collected at 1 h after
injury, which were used for the double immunohistochemistry with
p-cPLA2 (green) and NeuN (red). Control as well as Lpar1- and Lpar3-
deficient mice were also used in this experiment. White arrows
represent NeuN-co-localized p-cPLA2 signals. The capital letter “C”
and “I” represent control and nerve injury, respectively. The “veh”,
“MK”, “CP”, “AA” and “mino” represent vehicle, MK-801, CP-99994,
AACOCF3 and minocycline, respectively. Scale bar, 50 μm.
Figure 6 LPA1 or LPA3 receptor-mediated calcium mobilization by ex
(panel b and g), 16:0 (panel c and h), 18:0 (panel d and i) or 14:0 (panel e a
10 μM) into the B103 cells expressing LPA1 or LPA3 receptor, calcium mobi
represent the half-maximal effective dose and maximal response, respectiv
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as no evident maximal effect was obtained with 18:0
LPA in the range of concentrations we used, its ED50
value was not determined. Similar results were also
observed in the cases with 18:1 and 20:4 LPA on LPA3-
B103 cells (Figure 6f and g). The values of ED50 were
272.3 and 148.3 nM, respectively, and maximal re-
sponses were 100% and 97.8%, respectively. Compared
with these two species of LPA, the calcium mobilization
by 16:0, 18:0 and 14:0 LPA was so weak that their values
of ED50 and maximal responses were not determined
(Figure 6h-j).
Measurement of amplified LPA production by exogenous
LPA injection
We previously demonstrated that i.t. LPA injection
enabled to feed-forward amplify LPA [29]. In order to
identify the key species of LPA molecule in charge of
LPA amplification, we i.t. injected three species of LPA
(18:1, 16:0 and 18:0 LPA), which were produced by
nerve injury, and evaluated amplified LPA production by
use of MALDI-TOFMS system. As shown in Figure 7a,
after 18:1 LPA injection at 1 nmol, 18:1 LPA itself was
newly produced, and the level immediately increased (in-
dicated as 0 h). The elevation may be attributed to the
sum of the basal and injected 18:1 LPA. Subsequently,
the progressive increase in the level of 18:1 LPA was ob-
served at 1 h, reached a maximum at 3 h, and slightly
declined at 6 h. Besides 18:1 LPA, 16:0 and 18:0 LPAogenous LPA species. After the addition of 18:1 (panel a and f ), 20:4
nd j) LPA with defined concentrations (3, 10, 30, 100, 300 nM and 1, 3,
lization assay was immediately performed. “ED50” and “Max resp”
ely.
Figure 7 Amplification of LPA production by injection of LPA species. (a) Levels of LPA species (18:1, 16:0 and 18:0 LPA) in the spinal dorsal
horn were measured by MALDI-TOFMS system at time-course points after i.t. 18:1 LPA injection with 1 nmol. (b) Measurements of LPA species
were performed at 3 h after 16:0 or 18:0 LPA injection with 10 nmol. The capital letter “C” represents the control group (naive mice). (c) After i.t.
injection of 18:1 LPA (1 nmol), 16:0 LPA (10 nmol) or 18:0 LPA (10 nmol), the pain behavior was evaluated by thermal paw withdrawal test.
Results represent the threshold of latency (s) to thermal stimulus. Data represent means ± SEM from experiments using 3-7 mice. *p < 0.05, versus
with the control/vehicle group; #p < 0.05, versus with the 0 h-LPA group.
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levels of these species of LPA were significantly increased
at 1 and 3 h, and slightly decreased at 6 h (Figure 7a).
On the other hand, the i.t. administration of 16:0 or
18:0 LPA at a high dose of 10 nmol failed to produce
any LPA production at 3 h (Figure 7b). Similarly, in the
nociceptive behavior experiments, 18:1 LPA injection
with 1 nmol induced neuropathic pain-like thermal
hyperalgesia, but 16:0 or 18:0 LPA with 10 nmol did
not (Figure 7c).
Discussion
This study demonstrates three major findings for the
first time. First, LPA with three species (18:1, 16:0 and
18:0 LPA) were produced after nerve injury with the use
of MALDI-TOFMS system. Second, p-cPLA2-expressed
neuron was the potent cell to release LPA through LPA1
and LPA3 receptors-mediated microglial activation. Third,18:1 LPA was a key ligand to induce amplification of LPA
production in the peripheral neuropathic pain model.
The present study successfully detected and quantified
several species of LPA molecules after nerve injury
through MALDI-TOFMS system with the use of Phos-
tag, a zinc complex that specifically binds to a phosphate
group [7,33,34]. This MS analysis using Phos-tag signifi-
cantly decreased the detection limit of LPA compared
with previous methods without Phos-tag [7,34]. More-
over, this technique improved our previous biological
titration method, because previous one depended solely
on the activity of LPA1 [6,29,35], but not LPA3 receptor,
which was the important determinant of LPA synthesis
[29]. Here, we found that three species of LPA, including
18:1, 16:0 and 18:0 LPA, were maximally produced in
the ipsilateral side of spinal dorsal horn, but not the
contralateral side, at 3 h after injury, followed by a de-
cline at 6 h. The time-course changes of LPA production
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This data firstly provided the chemical identification of
produced LPA after nerve injury, which was consistent
with the molecular species composition of produced
LPC (18:1, 16:0 and 18:0 LPC) [31]. Moreover, the quan-
titative levels of peak 18:1 LPA was approximately three-
or four-folds than that of 16:0 or 18:0 LPA, respectively,
suggesting that 18:1 LPA was the predominant molecu-
lar specie of spinal LPA production after nerve injury.
However, there was an interesting finding that in previ-
ous LPC measurements, the amount of produced 18:1
LPC was equivalent to or slightly lower than that of 16:0
and 18:0 LPC at 75 min after nerve injury [31]. The
difference may be attributed to the biochemical fact that
autotaxin, an enzyme to catalyze LPC conversion to
LPA, has the preferential affinity to 18:1 LPC than to
16:0 and 18:0 LPC [40].
In this study, pharmacological antagonist of NMDA or
NK1 receptor (MK-801 or CP-99994, respectively) com-
pletely blocked the nerve injury-induced LPA produc-
tion. Considering the fact that combination treatments
of SP and Glu (or NMDA), but not single treatment,
in vitro induced LPA production in spinal cord slices
[35], we believed that simultaneous intense stimulation
of NMDA and NK1 receptors was essential for new LPA
biosynthesis in the spinal cord. This proposition was
supported by the ex vivo study that capsaicin-induced
LPA production in spinal cord slices was completely
blocked by MK-801 or CP-99994 [35].
Additionally, both cPLA2 and iPLA2 were maximally
activated at 1 h after injury, being consistent with the
time point of LPA production at 3 h, because cPLA2 and
iPLA2 mediate PC hydrolysis into LPC, the precursor of
LPA [35-37]. It should be noted that activated cPLA2
slowly reduced to the basal level from 3 h, while iPLA2
activity rapidly decreased from 2 h. The difference might
be due to the distinct mechanisms of cPLA2 and iPLA2
activation, since cPLA2 can be activated by enhanced
level of intracellular calcium, as seen in the calcium in-
flux through NMDA receptor and calcium mobilization
from endoplasmic reticulum mediated by NK1 receptor,
while calcium-independent iPLA2 lacks the multiple
triggers [18]. Moreover, it was interesting that MK-801,
the antagonist of NMDA receptor, completely reversed
the increased cPLA2 activity, but partially inhibited
iPLA2 activity, which might be explained by the fact that
the activity of cPLA2, but not iPLA2, is calcium-dependent.
Furthermore, as BEL is a specific inhibitor of iPLA2 with
high potency (half-maximal inhibitory concentration: 60
nM) [38], in this study, it even decreased the elevated iPLA2
activity to the level lower than the basal one. In addition,
pharmacological blockade of cPLA2 or iPLA2 abolished
nerve injury-induced cPLA2 and iPLA2 activations as
well as LPA production.Usually, saturated fatty acyl chains (16:0 and 18:0) are
located in sn-1 position in phospholipids, while unsatur-
ated ones (18:1) are in sn-2 position. However, there is a
report that several PC molecules possess 18:1-chains in
both sn-1 and sn-2 positions, such as diacyl-18:1/22:6,
diacyl-18:1/20:4, diacyl-16:0/18:1 and diacyl-18:0/18:1, in
the spinal cord [41]. In this study, we found there was
no significant change in PLA1 activity after nerve injury.
Therefore, it is suggested that the production of 18:1
LPA isoform is mainly generated by the action of PLA2,
but not PLA1, and 18:1-fatty acyl chain is located in sn-1
position.
On the other hand, in this study, minocycline-induced
blockade of microglial activation at early phase signifi-
cantly inhibited nerve injury-induced LPA production
and increased PLA2 activations, which confirmed the
evidence that microglia plays important roles in LPA
production. Indeed, previous study showed that both
nerve injury and i.t. LPA injection induced phosphoryl-
ation of microglial p38 kinase, subsequent up-regulation
of microglial activation-related gene and morphological
change from ramified to amoeboid type [30].
Although the biomarker of activated iPLA2 is not
available so far, we performed immunohistochemistry
study to evaluate the cell-type expressing p-cPLA2 (acti-
vated cPLA2). It should be noted that p-cPLA2 was pre-
dominantly expressed in most of spinal neurons, with
minor ones in microglia. The neuron-colocalized p-
cPLA2 seemed to diffuse in slightly broader regions
(mainly laminae I-IV) of spinal dorsal horn. This broader
distribution was similar to the case with activated micro-
glia after the nerve injury [30]. Moreover, since most of
p-cPLA2-expressing neurons were observed in broader
regions of dorsal horn, but not in line-up regions at
superficial layers (lamina I-II), we speculated that the
neurons expressing p-cPLA2 might be the interneurons
in vicinity of microglia as well as second order neurons
receiving pain transmission from primary afferent neu-
rons. Considering that iPLA2 also predominantly ex-
presses in neurons [42,43], and LPA can be synthesized
and secreted by primary cultured neurons in vitro [44],
we can hypothesize that spinal neurons, especially sec-
ond order neurons and interneurons, are likely the cells
responsible for the release of LPC/LPA, and the machin-
eries may include the microglial activation.
It should be also noted that nerve injury-induced LPA
production and increased PLA2 activities were com-
pletely absent in Lpar1-/- and Lpar3-/- mice, suggesting
both LPA1 and LPA3 receptors were responsible for LPA
synthesis, being consistent with the findings that both
Lpar1-/- and Lpar3-/- mice abolished neuropathic pain
behavior in response to LPA injection or nerve injury
[20,29]. On the other hand, our RT-PCR results and
other reports demonstrated that both LPA1 and LPA3
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levels in neurons were reported to be limited [13,46],
indicating that microglial LPA1 and LPA3 receptors
might induce the release of biological factors, which in
turn activated cPLA2 or iPLA2 in neurons, leading to an
LPA production.
We found that both 18:1 and 20:4 LPA preferentially
activated LPA1 and LPA3 receptors, while 16:0, 18:0 and
14:0 LPA were poor agonists, being consistent with pre-
vious reports [47]. Since the level of 20:4 LPA in the
spinal dorsal horn was under detection limit, even after
nerve injury in the present MALDI-TOFMS system, it
was evident that 18:1 LPA is the most functionally
potent LPA molecule, which was produced after nerve
injury. On the other hand, we found that only 18:1 LPA,
but not 16:0 or 18:0 LPA, produced new LPA with three
species (18:1, 16:0 and 18:0 LPA) at 1-3 h, among which
18:1 LPA was also the predominant product. This result
was consistent with the behavior finding that only 18:1
LPA, but not 16:0 or 18:0 LPA, induced neuropathic
pain-like behavior. Given the fact that 18:1 LPA was the
most potent molecule to interact with both LPA1 and
LPA3 receptors, we can conclude that 18:1 LPA plays
major roles in LPA1 and LPA3 receptors-mediated amp-
lification of LPA production, possibly through microglial
activation.
Conclusion
The present study demonstrates that 18:1 LPA is the
major species of LPA in quantity and function in terms
of LPA-induced amplification of LPA production. The
mechanisms underlying the LPA production include the
pain transmission by Glu and SP as well as indirect
microglial activation, possibly through LPA1 and LPA3
receptors. The activation of cPLA2, which plays a key
role for the production of LPC or LPA, is identified to
be in neurons. Thus, produced LPA may work for the
self-amplification via neuron-glia network. Targeted in-
hibition of 18:1 LPA or related pathways may be the po-




Male C57BL/6 J mice (TEXAM corporation, Nagasaki,
Japan), homozygous mutant mice for the LPA1 [48] and
LPA3 [49] receptor genes (Lpar1
-/- and Lpar3-/-), and
their sibling wild-type mice from the same genetic back-
ground were used in this experiment. The subjects weighed
20-24 g. They were kept in a room maintained at 21 ± 2°C
and 55 ± 5% relative humidity with a 12 h light/dark
cycle, and had free access to a standard laboratory
diet and tap water. The procedures were approved by
the Nagasaki University Animal Care Committee, andcomplied with the fundamental guidelines for the proper
conduct of animal experiments and related activities in
academic research institutions under the jurisdiction
of the Ministry of Education, Culture, Sports, Science
and Technology, Japan.
Drugs
18:1 LPA, MK-801 and minocycline were purchased
from Sigma-Aldrich Co. (St. Louis, MO). 16:0, 17:0 and
18:0 LPA were purchased from Doosan Serdary Re-
search Laboratories (Toronto, Canada). Monoisotopic
68Zn2+-Phos-tag (Phos-tag®) was obtained from the
NARD Institute Ltd. (Hyogo, Japan) and MANAC
Incorporated group (Hiroshima, Japan). CP-99994 was
generously provided by Pfizer Pharmaceuticals (Sandwich,
Kent, UK). AACOCF3 and BEL were purchased from
Cayman Chemicals (Ann Arbor, MI).
For mass spectrometry experiments, various LPA spe-
cies were dissolved in methanol (Sigma, St. Louis, MO).
For in vivo experiments, all pharmacological antagonists
except for minocycline were dissolved in artificial cerebro-
spinal fluid (125 mM NaCl, 3.8 mM KCl, 1.2 mM
KH2PO4, 26 mM NaHCO3, 10 mM glucose). Minocycline
was dissolved in physiological saline.
Partial sciatic nerve ligation
Partial ligation of the sciatic nerves was performed
under anesthesia with pentobarbital (50 mg/kg, i.p.),
according to modified methods [6,30]. The common sci-
atic nerve of the right hind limb was exposed at the high
thigh level through a small incision and the dorsal half
of the nerve thickness was tightly ligated with a silk
suture.
Extraction of LPA from tissues
The unilateral dorsal half including dorsal horn (laminae
I-V) of the lumber (L4-L6) spinal cord was removed.
The averaged wet weight of the isolated unilateral spinal
cord in each mouse was approximately 6.15 mg tissue
weight. LPA were extracted from tissues according to
modified methods [7,34]. After their isolation, the tissue
samples were homogenized in 200 μl cold saline
containing 100 mM of o-vanadate and 1 mM of EDTA.
The homogenates were transferred into a glass tube
(13 × 100 mm), and mixed with 0.5 nmol of 17:0 LPA,
an internal standard, and 1 ml acetone. After vigorous
vortex and centrifugation at 1300 × g for 5 min, the
supernatant was discarded. The remaining pellet was
washed twice with 0.5 ml acetone again, and dried with
N2 gas. The dried pellet was mixed with 0.1 ml chloro-
form, 0.2 ml methanol and 0.08 ml water. After centrifu-
gation at 1300 × g for 5 min, the supernatant was
collected, and mixed with 0.2 ml chloroform, 0.2 ml 5%
potassium chloride potassium chloride and 0.001 ml
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1300 × g for 5 min, the supernatant was collected and
washed with 0.4 ml chloroform/methanol (17:3, v/v).
After washing for four times, 10 nmol of monoisotopic
68Zn2+-Phos-tag and 0.4 ml chloroform/methanol (17:3,
v/v) were added to the supernatant (water/methanol
phase). After shaking and centrifugation, the lower
chloroform phase was collected, and the remaining
water/methanol phase was extracted again. The com-
bined chloroform phases were dried with N2 gas. The
final sample was dissolved in 50 μl methanol containing
0.1% aqueous ammonia and stored at −20°C until use
for analysis.
MALDI-TOFMS analyses
One μl from 50 μl of finally obtained methanol solution
was spotted on an MALDI plate (Bruker Daltonics, Inc.,
CA, USA). Immediately, 1 μl of THAP solution (10 mg/ml
in acetonitrile; Sigma, St. Louis, MO) was layered on
the mixture as matrix solution. After drying, the sam-
ple was applied to an UltraflexTM TOF/TOF systems
(Bruker Daltonics, Inc., CA, USA). Mass spectrometry was
performed in the positive mode, using an accelerating volt-
age of 25 kV. The laser energy was used at energy of 30 –
70% (3.0 – 7.0 μJ) and a repetition rate of 10 Hz. The mass
spectra were calibrated externally using Peptide calibration
standard (Bruker Daltonics, Inc., CA, USA) as a standard
peptide calibration. Each spectrum was produced by accu-
mulating data of 1500 or 2500 consecutive laser shots.
Primary culture of mouse microglia
Glial cultures were prepared from the whole brain tis-
sues of 1-day-old C57BL/6 J mice and maintained for 8–
14 days in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (Gibco, Carlsbad,
CA, USA), 1% penicillin/streptomycin (final concentra-
tion 100 units/ml; Invitrogen, Tokyo, Japan). All medium
was changed every three days, from 24 h after the start
of culture. The microglia was obtained as floating cells
over the mixed glial culture, and seeded onto 6-well
plate with the density of 1.0 × 105 cells/cm2. After incu-
bation at 37°C in a 5% CO2 atmosphere overnight, we
removed the medium and added 400 μl TRIzol
(Invitrogen, Carlsbad, CA, USA) into each well for
RT-PCR experiment.
RT-PCR
The expression levels of LPA receptors were evaluated
by RT-PCR, according to described method [29,50].
Cultured microglia and isolated L4-6 SC from naive
mice were lysed with TRIzol for RNA preparation. Total
RNA (1 μg/sample) was used for cDNA synthesis with
PrimeScript® RT reagent Kit (Takara, Otsu, Japan). The
cycling conditions for all primers were 3 min at 95°C,then 50 cycles of 30 s at 95°C, 30 s at 55°C and 2 min at
72°C. The PCR primer sequences were as follows: LPA1,
5’-ATCTTTGGCTATGTTCGCCA-3’ (forward) and 5’-
TTGCTGTGAACTCCAGCCA-3’ (reverse); and for LPA3,
5’-TTGCCTCTGCAACATCTCGG-3’ (forward) and 5’-C
ATGACGGAGTTGAGCAGTG-3’ (reverse). Then, the
PCR products were analyzed by 1.5% agarose gel
electrophoresis.
Thermal paw withdrawal test
In this test, nociception was measured as the latency to
paw withdrawal evoked by exposure to a thermal stimu-
lus [6,30,51,52]. Unanesthetized animals were placed in
Plexiglas cages on top of a glass sheet and allowed an
adaptation period of 1 h. A thermal stimulator (IITC
Inc., Woodland Hills, CA) was positioned under the
glass sheet and the focus of the projection bulb was
aimed precisely at the middle of the plantar surface of
the animal. A mirror attached to the stimulator permit-
ted visualization of the plantar surface. A cut-off time of
20 s was set to prevent tissue damage.
Phospholipase A2 activity assays
The activities of cPLA2 and iPLA2 were detected using
the following assays as described previously [6,30,53].
Briefly, ipsilateral side of spinal dorsal horn was re-
moved. After sonication and centrifugation at 20000 × g
for 20 min at 4°C, the supernatant was collected and
kept on ice. The protein concentration of the super-
natant was determined by the Lowry method, and the
assays were performed using a cPLA2 assay kit (Cayman
Chemicals, Ann Arbor, MI, USA) to evaluate the cPLA2
activity or a modified cPLA2 assay kit (Cayman Chemicals,
Ann Arbor, MI, USA) to evaluate the iPLA2 activity, as
described previously [53]. In the cPLA2 assay, the tissue
samples were incubated with both BEL, an iPLA2 inhibitor
[38], and a substrate, arachidonoyl thio-PC, at 20°C for
1 h in a assay buffer. The reactions were stopped by
DTNB/EGTA for 5 min, and the absorbances were deter-
mined at 405 nm using a standard plate reader. To detect
the activity of iPLA2, but not cPLA2, the samples were in-
cubated with the substrate, arachidonoyl thio-PC, at 20°C
for 1 h in a modified Ca2+-free buffer [4 mM EGTA,
160 mM HEPES pH 7.4, 300 mM NaCl, 8 mM Triton
X-100, 60% glycerol, 2 mg/ml of bovine serum albumin
(BSA)]. The reactions were stopped by the addition of
5,5’-dithiobis(nitrobenzoic acid) for 5 min. The activity of
PLA2 was defined as the percentage of the control activity
as follows: injured tissues (absorbance/mg of protein)/
normal tissues (absorbance/mg of protein) × 100.
Phospholipase A1 activity assay
PLA1 activity assay was performed according to the
manufacturer’s protocol of EnzChek® phospholipase A1
Ma et al. Molecular Pain 2013, 9:29 Page 12 of 14
http://www.molecularpain.com/content/9/1/29assay kit (Invitrogen, Molecular Probes, OR, USA).
Briefly, isolated ipsilateral spinal dorsal horn was soni-
cated in PLA1 reaction buffer (50 mM Tris-HCl, 0.14 M
NaCl, 2 mM CaCl2, pH 7.4) and centrifuged at 20000 × g
for 20 min at 4°C. The supernatant was collected and its
protein concentration was determined by the Lowry
method. In the PLA1 assay, the substrate-liposome mix
was prepared by mixing 9 μl of lipid mix [3 μl of
dioleoylphosphatidylcholine (10 mM; Sigma-Aldrich,
St. Louis, MO), 3 μl of dioleoylphosphatidylglycerol
(10 mM; Sigma-Aldrich, St. Louis, MO) and 3 μl of
PLA1 substrate (1 mM PED-A1; Invitrogen, Molecular
Probes, OR, USA)] and 501 μl of PLA1 reaction buffer.
Subsequently, 1 μl of tissue sample, standard PLA1
(Sigma-Aldrich, St. Louis, MO) or negative control (PLA1
reaction buffer) was incubated with 19 μl of substrate-
liposome mix in a 384-well microplate (Greiner bio-one,
Frickenhausen, Germany) for 30 min. Then the fluor-
escence was measured using a PHERAstar FS reader
(BMG-Labtech, Offenburg, Germany) equipped for
excitation at 485 nm and fluorescence emission at
520 nm. The activity of PLA1 was defined as the per-
centage of the control activity as follows: injured tissues
(absorbance/mg of protein) / normal tissues (absorbance/
mg of protein) × 100.
Immunohistochemistry
Mice were deeply anesthetized with pentobarbital (50 mg/kg)
and perfused with potassium-free phosphate buffered
saline (pH7.4), followed by 4% paraformaldehyde solution.
L4-6 spinal cord segments were then isolated, postfixed in
the same fixative for 3 h, and replaced with 25% sucrose
overnight. Tissues were fast-frozen in cryo-embedding
compound and cut on a cryostat at a thickness of 10 μm.
Immunofluorescence labeling was performed by blocking
the sections with 2% BSA in TBST (0.1% Triton X-100 in
Tris Buffered Saline) for 2 h at 20°C, followed by
incubation with anti-NeuN antibody (1:500; anti-mouse,
Chemicon, CA) or anti-Iba1 antibody (1:250; anti-goat,
Abcam, Cambridge, UK) overnight at 4°C. After washing,
sections were incubated with Alexa Fluor 594-conjugated
anti-mouse IgG (1:300; Invitrogen, Carlsbad, CA) or Alexa
Fluor 546-conjugated anti-goat IgG (1:300; Invitrogen,
Carlsbad, CA), respectively, for 2 h at 20°C. Then, sections
were blocked with 2% BSA in TBST for 2 h at 20°C and
incubated overnight at 4°C with anti-phospho-cPLA2
antibody (anti-rabbit, 1:100; Abcam, Cambridge, UK).
Sections were subsequently incubated with secondary
antibody, Alexa Fluor 488-conjugated anti-rabbit IgG
(1:300; Invitrogen, Carlsbad, CA), for 2 h at 20°C. Stained
sections were washed and cover-slipped with Perma Fluor
(Thermo Shandon, Pittsburgh, PA, USA). Images were
collected using an LSM 710 confocal microscope with
ZEN software (Carl Zeiss, Oberkochen, Germany).Calcium mobilization assay
LPA1-B103 or LPA3-B103 cells were used for calcium
mobilization assay. The cells were harvested by centrifu-
gation and re-suspended with 0.1% BSA supplied-
DMEM. The cell suspension was plated 30 μl per well in
a 384-well plate with the density of 5.0 × 103 cells/well.
Following incubation at 37°C in a 5% CO2 atmosphere
overnight, cells were loaded with 10 μl Fluo-8 (8 μM) in
0.1% BSA supplied-DMEM containing 1 mg/ml amaranthl.
After 30 min, 20 μl various LPA species at defined concen-
tration was added, and fluorescence was recorded by
Functional Drug Screening System/μCell (Hamamatsu
Photonics K.K., Hamamatsu city, Japan) immediately. The
fluorescence intensity was described as signal ratio (tested
value / basal value).
Statistical analysis
Statistical analysis was evaluated using the Tukey’s
multiple comparison post hoc analysis following one-way
ANOVA. The criterion of significance was set at
p < 0.05. All results are expressed as mean ± SEM.
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